MiNK Therapeutics (NASDAQ:INKT) Given New $4.00 Price Target at Robert W. Baird

MiNK Therapeutics (NASDAQ:INKT) had its target price reduced by Robert W. Baird from $8.00 to $4.00 in a research report released on Friday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 price target on shares of MiNK Therapeutics in a research note on Wednesday, October 9th.

MiNK Therapeutics Stock Down 7.8 %

Shares of NASDAQ:INKT opened at $0.70 on Friday. MiNK Therapeutics has a fifty-two week low of $0.57 and a fifty-two week high of $1.90. The firm’s 50-day simple moving average is $0.73 and its 200-day simple moving average is $0.85. The company has a market cap of $27.48 million, a price-to-earnings ratio of -1.78 and a beta of 0.05.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Renaissance Technologies LLC raised its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 127,841 shares of the company’s stock after purchasing an additional 22,613 shares during the period. Renaissance Technologies LLC owned about 0.37% of MiNK Therapeutics worth $121,000 at the end of the most recent reporting period. Institutional investors own 2.87% of the company’s stock.

About MiNK Therapeutics

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.